Supreme Court to Drug Makers: No More ‘Pay to Delay’

What's Hot

23 Upgrades Under $50 to Make Your House Look AwesomeAround The House

Trump Worth $10 Billion Less Than If He’d Simply Invested in Index FundsBusiness

Do This or Your iPhone Bill May SkyrocketSave

11 Places in the World Where You Can Afford to Retire in StyleMore

19 Moves That Will Help You Retire Early and in StyleFamily

What You Need to Know for 2017 Obamacare EnrollmentFamily

8 Things Rich People Buy That Make Them Look DumbAround The House

50 Ways to Make a Fast $50 (or Lots More)Grow

32 of the Highest-Paid American SpeakersMake

The 35 Two-Year Colleges That Produce the Highest EarnersCollege

5 DIY Ways to Make Your Car Smell GreatCars

Amazon Prime No Longer Pledges Free 2-Day Shipping on All ItemsMore

More Caffeine Means Less Dementia for WomenFamily

7 Household Hacks That Save You CashAround The House

5 Reasons a Roth IRA Should Be Part of Your Retirement PlanGrow

30 Awesome Things to Do in RetirementCollege

Beware These 10 Retail Sales Tricks That Get You to Spend MoreMore

9 Tips to Ensure You’ll Have Enough to RetireFamily

A brand-name company that tries to pay its generic competition to go away can now be sued for violating antitrust laws.

Pharmaceutical companies pay generic drug makers millions of dollars a year to keep their cheaper products off of the market. It’s a relatively cheap way to keep prices high and maintain profits, as we’ve written before. The practice has been called “pay to delay.”

Now, because of a new U.S. Supreme Court decision, the practice could cost drug makers in ways they hadn’t expected. The justices ruled 5-3 that brand-name drug companies can be sued under antitrust laws if they make such agreements, the Los Angeles Times says.

The ruling will likely lead to lower prices, the newspaper says; the Federal Trade Commission has said these back-room deals cost consumers and health plans $3.5 billion a year.

But it’s not an outright win for the FTC, which argued that the deals were usually illegal.

Instead, these arrangements will be judged on a case-by-case basis, the Times says. The court said drug makers can be sued, but the facts of each case will determine whether the payoff was reasonable to settle a patent dispute or an attempt to block competition.

Drug makers already get a long time to dominate the market before their patents expire. Patents can last as long as 20 years, the Times writes, and can often be extended an additional 20 years by tweaking the formula or how the drug is administered. But generic makers can challenge the extended monopoly, and that’s when these “pay to delay” settlements come into play.

Stacy Johnson

It's not the usual blah, blah, blah

I know... every site you visit wants you to subscribe to their newsletter. But our news and advice is actually worth reading! For 25 years, I've been making people richer without making their eyes glaze over. You'll be glad you did. I guarantee it!


Read Next: How Does Debt Affect Survivors After a Loved One’s Death?

Check Out Our Hottest Deals!

We're always adding new deals and coupons that'll save you big bucks. See the deals to the right and hundreds more in our Deals section.

Click here to explore 1,640 more deals!